No Data
Brokerage morning meeting highlights: Now is the right time for AI healthcare layout.
In today's Brokerage morning meeting, Sinolink proposed that the layout of AI in healthcare is timely; HTSC expressed a bullish outlook on the product upgrades and commercial breakthroughs of AI applications in China by 2025; China Securities Co.,Ltd. believes that the turning point in the IDC Industry is approaching, and a new cycle is expected to begin.
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
Luye Pharma Group's (HKG:2186) Earnings Have Declined Over Five Years, Contributing to Shareholders 55% Loss
LUYE PHARMA is a low-value buy.
Hong Kong stocks experienced brief fluctuations due to external influences, and LUYE PHARMA (2186.HK) is less than ten percent away from its temporary 52-week low of 1.97 yuan (recorded on February 3 this year). Additionally, it has been at low levels since December 2022, which is over two years and two months ago, indicating strong defensiveness. The group is committed to developing, producing, promoting, and selling Innovative Drugs in the four largest and fastest-growing therapeutic areas globally, namely oncology, central nervous system, cardiovascular system, and digestive and metabolic fields in China, the USA, Europe, and Other countries or regions. The announcement regarding the fiscal year 2024 was released after the market closed on September 29 last year.
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.
① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?
